Trial Profile

A Phase 2/3 Trial of T-COVID for COVID-19 Infections

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 06 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs T-COVID coronavirus vaccine-Altimmune (Primary)
Indications COVID 2019 infections
Focus Registrational; Therapeutic Use
Sponsors Altimmune

Most Recent Events

06 Jul 2020 New trial record
29 Jun 2020 According to an Altimmune media release, if the Phase 1/2 clinical trial is successful, the Company plans to initiate this Phase 2/3 trial of T-COVID early next year and commence discussions regarding a potential Emergency Use Authorization.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com